NovaQuest launches “pharma” fund targeting US$850 million

In 2015, NovaQuest Capital Management (“NovaQuest”) launched its fourth fund, Pharma Opportunities Fund IV, LP, seeking $750 million to invest in the development of new pharmaceutical drugs, which it later increased to $850 million. NovaQuest Capital Management is a leading investor in life sciences and healthcare, and routinely provides capital to large global biopharmaceutical companies that need help developing new drugs. Fasken Martineau acted as Canadian counsel to NovaQuest Capital Management in connection with the Fund IV with a team that included Daniel Fuke and Tracy Hooey.